New Two-Drug attack on advanced cervical cancer enters human testing
NCT ID NCT07080216
Summary
This study is testing a new combination of two drugs, ZG005 and gecacitinib, for women with advanced cervical cancer. The main goals are to find a safe dose and see if the treatment can shrink tumors. It will enroll about 120 participants to gather initial data on safety and effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact
Conditions
Explore the condition pages connected to this study.